35
Participants
Start Date
November 1, 2007
Primary Completion Date
October 31, 2009
Study Completion Date
November 30, 2010
Temsirolimus
Given intravenously every week of each 28-day cycle (days 1, 7, 15, 22). Participants can continue to receive study treatment as long at their tumor is responding.
Cetuximab
One dose is given intravenously 7 days prior to the start of each 28-day cycle, then it is given every week (along with temsirolimus)of each 28-day cycle (on days 1, 7, 15, 22). Participants can continue to receive study treatment as long at their tumor is responding.
Massachusetts General Hospital, Boston
Dana-Farber Cancer Institute, Boston
Dana-Farber Cancer Institute
OTHER
Brigham and Women's Hospital
OTHER
Wyeth is now a wholly owned subsidiary of Pfizer
INDUSTRY
Jeffrey W. Clark, MD
OTHER